Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.85
COGNITION THERAPEUTICS INC reported the year ended December 31, 2022 results: net income approximately $21.4 million.
- Period
- the year ended December 31, 2022
- Net income
- approximately $21.4 million
- Result
- preliminary results
Exact text from the filing
Preliminary unaudited operating results for the year ended December 31, 2022 and certain preliminary financial condition information as of December 31, 2022 are as follows: · Net loss for the year ended December 31, 2022 is expected to be approximately $21.4 million. · As of December 31, 2022, the Company had approximately $41.6 million in cash and cash equivalents.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.99
COGNITION THERAPEUTICS INC entered into Purchase Agreement with Lincoln Park Capital Fund, LLC valued at up to $35,000,000 (effective 2023-03-10).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- Lincoln Park Capital Fund, LLC
- Value
- up to $35,000,000
- Effective
- 2023-03-10
Exact text from the filing
Cognition Therapeutics, Inc. (the “Company”) entered into a purchase agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), which provides that, upon the terms and subject to the conditions and limitations set forth therein, the Company has the right, but not the obligation, to sell to Lincoln Park up to $35,000,000 of shares of the Company’s common stock
View on SEC.gov